Lupin Ltd falls as much as 7.7 pct to its lowest since Aug. 8, 2014.
Pharma company posted a 49 pct fall in consolidated net profit for the March quarter, missing analysts' estimates.
Says it expects more pricing pressure in the United States and is currently seeing price erosion in the high single digits.
"U.S. business will continue to see pressure in FY18 and growth will be a challenge led by increased competition in key products and elevated pricing pressure," analysts at Jefferies write.
Stock set to post fourth straight session of losses.
Stock has fallen 17.4 pct this year as of Wednesday's close.
